Page 5,917«..1020..5,9165,9175,9185,919..5,9305,940..»

Leading Pharmacy Benefits Manager to Pilot Mattersight's Predictive Behavioral Routing to Reduce Customer Service …

Posted: Published on January 3rd, 2013

CHICAGO, IL--(Marketwire - Jan 2, 2013) - Mattersight Corporation ( NASDAQ : MATR ) today announced the signing of another pilot contract for its Predictive Behavioral Routing solution.The pilot is with an existing customer that is among the largest pharmacy benefits managers in the United States. In the pilot, Mattersight will integrate its Predictive Behavioral Routing solution into the customer's existing Cisco routing architecture to reduce customer service costs and improve customer satisfaction. Mattersight's Predictive Behavioral Routing solution identifies the optimal customer/employee pairing for each individual caller based upon communication styles, personality mapping, and behavioral characteristics.This information is utilized by the existing routing architecture to match customers with the best available employee, thus increasing the likelihood of a behavioral connection.As a result, companies are capable of driving an immediate 10%-50% reduction in costs, improvement in sales, reduction in attrition, improvement in first call resolution, or increase in customer satisfaction or Net Promoter Scores (NPS). Mattersight recently announced a new trial program of its innovative Predictive Behavioral Routing solution.Details of the new program include: For more information on Mattersight's Trial Program or on the Predictive Behavioral Routing solution, please send requests to: info@mattersight.com or visit http://www.Mattersight.com/trialoffer. Net Promoter, NPS, and Net … Continue reading

Posted in Pharmacy | Comments Off on Leading Pharmacy Benefits Manager to Pilot Mattersight's Predictive Behavioral Routing to Reduce Customer Service …

This Struggling Pharmacy Ended 2012 On a High Note

Posted: Published on January 3rd, 2013

By Eric Novinson - January 2, 2013 | Tickers: CVS, RAD, WMT, WAG | 0 Comments Eric is a member of The Motley Fool Blog Network -- entries represent the personal opinions of our bloggers and are not formally edited. Rite Aid (NYSE: RAD) investors finally got their turnaround signal, as generic drug sales and efficiency gains helped return the pharmacy chain to profitability last quarter. A profitable Rite Aid poses a bigger challenge for CVS (NYSE: CVS) and Walgreens (NYSE: WAG) as well, and these competitors can also benefit from a major trend that helped Rite Aid during the quarter. Rite Aid has three main arguments in its favor right now. Valuation Rite Aid looks very cheap for a major, national drugstore chain. The pharmacy traded below $1 a share several times in 2012. On Dec. 19, 2012, before its earnings release, the pharmacy's shares traded at $1.04. The earnings release the next day started an uptrend in Rite Aid's shares, and Rite Aid held on to most of its gains, closing at $1.36 on Dec. 31, 2012. Because of Rite Aid's past losses, forecasts based on the drugstore's prior earnings history might not account for its current potential. … Continue reading

Posted in Pharmacy | Comments Off on This Struggling Pharmacy Ended 2012 On a High Note

Pharmacy robberies in Maine double in 2012

Posted: Published on January 3rd, 2013

PORTLAND, Maine Pharmacy robberies in Maine more than doubled last year over 2011, and police are concerned the robberies are becoming more brazen. There were 56 pharmacy robberies last year, with drug addicts taking increasingly desperate measures, said Steve McCausland of the Department of Public Safety. In one instance, a man robbed a pharmacy inside a Walmart filled with customers in broad daylight. "These are desperate acts by desperate people, and from a law enforcement perspective, it's extremely troubling because of potential violence," McCausland said. The troubling trend that led a national pharmacy chain to post armed security guards and the establishment of a state panel to identify solutions came in a year that otherwise was relatively safe, McCausland said. Suspects who robbed pharmacies at a rate of more than one per week last year were seeking narcotics for the most part. Common targets were oxycodone, the key ingredient in the painkiller OxyContin, and hydrocodone, the ingredient in painkillers Vicodin and Xanax, a drug used to treat anxiety and panic attacks. There were no deaths or injuries during the robberies, but police fear that could change as drug addicts, sometimes armed, become increasingly erratic. In Bangor, a man charged with … Continue reading

Posted in Pharmacy | Comments Off on Pharmacy robberies in Maine double in 2012

FDA Clears OncoMed’s Demcizumab (Anti-DLL4) to Resume Clinical Testing in the US

Posted: Published on January 3rd, 2013

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- OncoMed Pharmaceuticals, a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that the U.S. Food and Drug Administration (FDA) has removed a partial clinical hold on its demcizumab (OMP-21M18) clinical program. Demcizumab is a humanized monoclonal antibody that targets Delta Like Ligand 4, or DLL4, in the Notch signaling pathway. Jakob Dupont, MD, OncoMeds Chief Medical Officer, stated, We are pleased that the FDA has responded favorably to the demcizumab clinical data and development strategy and removed the partial clinical hold to allow further development of demcizumab in the United States. OncoMed had submitted an extensive data package to the FDA with safety and efficacy results from four demcizumab clinical trials: a Phase 1a solid tumors study and three Phase 1b studies in non-small cell lung cancer (NSCLC), pancreatic cancer and colorectal cancer. The company plans to initiate new demcizumab clinical trials in 2013 in the United States. Specifically, the company will initiate a Phase 1b/2 study of demcizumab and paclitaxel in patients with epithelial ovarian cancer in collaboration with Drs. Robert Coleman and Anil Sood at the MD Anderson Cancer Center (MDACC) as part of the MDACC … Continue reading

Posted in FDA Stem Cell Trials | Comments Off on FDA Clears OncoMed’s Demcizumab (Anti-DLL4) to Resume Clinical Testing in the US

EastBridge Investment Group announces Cellular BioMedicine Group a keynote speaker at New York Stem Cell Summit

Posted: Published on January 3rd, 2013

PHOENIX, Jan. 2, 2013 /PRNewswire/ -- EastBridge Investment Group Corporation (EBIG), a provider of financial consulting services to companies in Asia ("EBIG") today announced Cellular BioMedicine Group ("CBMG") has been invited to give a keynote speech at the 8th Annual New York Stem Cell Summit, February 19, 2013. Dr. William Cao, president of CBMG , will deliver the keynote speech for CBMG. EastBridge plans to merge with CBMG in January, 2013. About Cellular Biomedicine GroupCellular Biomedicine Group, Ltd. is in the development of cell therapies for the treatment of certain cancer and degenerative diseases. Our developmental stem cell, progenitor cell, and immune cell projects are the result of collaborative research and development between scientists and doctors from the U.S. and China. Its flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: http://www.cellbiomedgroup.com About EastBridgeEastBridge Investment Group focuses on high-growth companies in Asia and in the United States, offering assistance with all aspects of IPOs, joint ventures and merchant banking services. EastBridge targets industries in the fields of electronics, real estate, auto, metal, energy, environmental, bioscience and retail food distribution. To learn more about … Continue reading

Comments Off on EastBridge Investment Group announces Cellular BioMedicine Group a keynote speaker at New York Stem Cell Summit

Bangkok Stem Cell Fat Graft Face Lift, Natural Breast Augmentaion & Brazillian Butt Lift Thailand at Cost-Effective!

Posted: Published on January 3rd, 2013

Food and Healthcare Press Releases Wednesday January 2, 2013 Bangkok--2 Jan--Urban Beauty Thailand Beauty is one of the greatest treasures in everyones life. Everyone is aware enough of the new technologies that arise in our society nowadays. One of them is the stem cells that would perfectly give you the youthful beauty that you wanna have. Thailand stem cell is a cell that can develop into different types of tissue based on where it is placed in the body. As a result, their potential for regeneration and restoration of old to new is enormous. Although most stem cell therapies for anti-aging are still new, some plastic surgeons are offering stem cell facelift. A stem cell facelift in Thailand is a cosmetic procedure that purportedly uses your own stem cells to remove signs of aging - sagging skin, wrinkles, and decreased facial fullness. Stem cell facelifts have been marketed as a new facial rejuvenation tool. On the other hand, many women dream of a natural-looking and permanent breast augmentation. Breast augmentation with the Adistem Stem Cell Technology in Thailand, is a gentle procedure that makes this dream a reality without silicone and other artificial fillers, without scars, without general anesthesia, and … Continue reading

Comments Off on Bangkok Stem Cell Fat Graft Face Lift, Natural Breast Augmentaion & Brazillian Butt Lift Thailand at Cost-Effective!

Canadian clinic first in country to harvest stem cells derived from body fat

Posted: Published on January 2nd, 2013

CTVNews.ca Staff Published Tuesday, Jan. 1, 2013 10:05PM EST Wishing that stubborn ring of belly fat would just disappear? Think twice about willing it away completely. Physicians at a Toronto clinic now consider it biological insurance that can be stored for a rainy day. Adisave, a clinic specializing in stem-cell harvesting, has begun offering storage of stem cells from human body fat, claiming the biological material can be used as a medical tool to repair and rejuvenate the body. Debra Seed opted for liposuction treatment to remove fat from her body and is paying $1,700 to have stem cells extracted, frozen and stored at Adisave-- the first clinic in the country to offer fat stem cell banking. They can put them back in my body and rejuvenate the bad cells, she said. Dr. Sammy Sliwin, a plastic surgeon and medical director at Adisave, has been working in fat grafting since 1992. He began doing research on mesenchymal stem cells in 2008. According to Sliwin, fat, or adipose tissue, contains 500 times more stem cells compared to bone marrow. Studies suggest they may have the power to repair injuries, damaged hearts and treat illness, he said. Its the most plentiful source … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on Canadian clinic first in country to harvest stem cells derived from body fat

Embryology Part 2 – Video

Posted: Published on January 2nd, 2013

Embryology Part 2شرحلـد.خالدالحداددوكتوربقسمطبالفمكليةطبأسنانجامعةعينشمس Embryology lectured by Dr. Khaled El-Hadad doctor of Oral Biology Department Faculty of Dentistry Ainshams University By:محمدياسرالجيوشي … Continue reading

Posted in Embryology | Comments Off on Embryology Part 2 – Video

Inovelon® (rufinamide) Oral Suspension Formulation Launched in Spain

Posted: Published on January 2nd, 2013

Lennox-Gastaut syndrome Inovelon(R) (rufinamide) oral suspension for adjunctive (add-on) treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in children four years and older is launched today in Spain. As many patients who receive the orphan drug rufinamide are children, the new formulation has been developed as a child friendly drinkable liquid to aid the administration of treatment. "As some children find tablets difficult to swallow, there is a strong need for drinkable medicines especially when treating younger LGS patients. In addition, the use of the rufinamide oral suspension allows for individual titration in smaller steps to find the optimal dose for each patient", said Dr. Juan Jose Garcia Peas, Neuropediatrician at the Hospital Infantil Universitario Nio Jesus. "The availability of the suspension formulation of rufinamide will potentially help young patients adhere better to treatment which should help improve outcomes in the management of this severe and highly debilitating disease." LGS is a rare form of epilepsy accounting for five percent of all cases and rising to approximately 10 percent of childhood epilepsy cases.[1] The annual incidence of the condition affects about 2.8 per 10,000 births in Europe.[1] Effective LGS management and compliance to treatment is of key importance to children … Continue reading

Comments Off on Inovelon® (rufinamide) Oral Suspension Formulation Launched in Spain

Dr. Marcelo Lancman, Medical Director of the Northeast Regional Epilepsy Group (NEREG) of New York and New Jersey …

Posted: Published on January 2nd, 2013

What You Need to Know if Epilepsy Has Touched Your Life: A Guide in Plain English is meant for patients, family members and health professionals alike. In this book, epilepsy expert, Dr. Marcelo Lancman shares his extensive knowledge on epilepsy in a way all can understand. New York, NY (PRWEB) January 02, 2013 With almost 3 million people in the U.S. having some form of epilepsy, and one in ten adults likely to experience a seizure during their life, it is tremendously important that as many people as possible are well informed about epilepsy facts. Epilepsy medicine is a rapidly growing field that can be hard to keep up with from a patients perspective. Presently, there are more than 20 available anti-epilepsy medications, as well as electronic treatment devices, diet therapies, and new state-of-the art diagnostic tools. This book covers these topics in a clear and understandable way as well as going over many important lifestyle issues that come up when epilepsy touches your life. For an interview or comments, please contact: Lorna Myers, Ph.D. at lmyers(at)epilepsygroup(dot)com or 212-661-7460, extension: 5. http://www.epilepsygroup.com Launched in 1998, NEREG is a multi-site practice in New Jersey, New York and Connecticut that offers unique … Continue reading

Comments Off on Dr. Marcelo Lancman, Medical Director of the Northeast Regional Epilepsy Group (NEREG) of New York and New Jersey …

Page 5,917«..1020..5,9165,9175,9185,919..5,9305,940..»